ACADIA PHARMACEUTICALS INC 4

4 · ACADIA PHARMACEUTICALS INC · Filed Sep 13, 2013

Form 4

Period: 2013-09-12

Director

Transactions

Exercise/Conversion
Common Stock
2013-09-12$6.10/sh+50$305→ 8,550 total
Exercise/Conversion
Common Stock
2013-09-12$8.85/sh+6,500$57,525→ 15,050 total
Exercise/Conversion
Common Stock
2013-09-12$2.16/sh+34,722$75,000→ 74,856 total
Sale
Common Stock
2013-09-12$22.90/sh−66,356$1,519,672→ 8,500 total
Exercise/Conversion
Stock option (right to buy)
2013-09-12−6,500→ 0 total
Exercise: $8.85Exp: 2015-06-09→ Common stock (6,500 underlying)
Exercise/Conversion
Stock option (right to buy)
2013-09-12−5,084→ 0 total
Exercise: $8.85Exp: 2015-06-09→ Common stock (5,084 underlying)
Exercise/Conversion
Stock option (right to buy)
2013-09-12−10,000→ 0 total
Exercise: $2.16Exp: 2019-06-11→ Common stock (10,000 underlying)
Exercise/Conversion
Common Stock
2013-09-12$8.85/sh+5,084$44,993→ 20,134 total
Exercise/Conversion
Common Stock
2013-09-12$9.04/sh+10,000$90,400→ 30,134 total
Exercise/Conversion
Common Stock
2013-09-12$2.16/sh+10,000$21,600→ 40,134 total
Exercise/Conversion
Stock option (right to buy)
2013-09-12−10,000→ 0 total
Exercise: $9.04Exp: 2016-06-12→ Common stock (10,000 underlying)
Exercise/Conversion
Stock option (right to buy)
2013-09-12−34,722→ 0 total
Exercise: $2.16Exp: 2019-06-11→ Common stock (34,722 underlying)
Exercise/Conversion
Stock option (right to buy)
2013-09-12−50→ 4,450 total
Exercise: $6.10Exp: 2014-06-13→ Common stock (50 underlying)

Footnotes (6)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2013.
[F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.64 to $23.30 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
[F3]25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following March 12, 2004.
[F4]25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 10, 2005.
[F5]25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2006.
[F6]25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 12, 2009.

Documents

2 files